Fortrea Holdings Inc. ( (FTRE) ) has released its Q2 earnings. Here is a breakdown of the information Fortrea Holdings Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fortrea Holdings Inc. is a global contract research organization specializing in clinical development solutions for the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies to accelerate healthcare innovation. In its second quarter of 2025, Fortrea reported revenues of $710.3 million, but faced a GAAP net loss of $374.9 million due to a significant non-cash goodwill impairment charge. Despite this, the company achieved an adjusted EBITDA of $54.9 million and adjusted net income per diluted share of $0.19, reflecting a positive operational performance. Key financial metrics included a book-to-bill ratio of 0.79x for the quarter and 1.10x for the trailing 12 months, with revenue guidance for 2025 raised to a range of $2,600 million to $2,700 million. The company also affirmed its adjusted EBITDA guidance for the year. Looking forward, Fortrea is optimistic about its growth potential under the leadership of new CEO Anshul Thakral, focusing on strengthening customer partnerships and enhancing shareholder value.